Type 1 diabetes medications

Read our Hot Topic Review for a rapid update on the successes and failures of immunotherapies in people with or at high risk for type 1 diabetes.

People with type 1 diabetes treated with multiple daily insulin injections struggle to achieve guideline-recommended targets for time in hypoglycemia while simultaneously reaching their glycated hemoglobin goals, researchers report.

Continuous subcutaneous insulin infusion users have more stable glycated hemoglobin levels over the long term than multiple daily injection users with type 1 diabetes, a real-world study suggests.

Factors associated with poor glycemic control in children with type 1 diabetes generally vary according to the insulin regimen used, but family conflict over diabetes management universally impacts all insulin users, US researchers report.

DIY closed-loop insulin delivery has provoked controversy within the diabetes community, raising questions around patient empowerment, safety and liability, and whether the regulatory process remains fit for purpose in a technological age. medwireNews takes a look at the issues.

Experts have developed consensus recommendations for minimizing diabetic ketoacidosis risk in patients with type 1 diabetes treated with SGLT inhibitors.

Insulin manipulation, the practice of deliberately under- or overdosing insulin, is strongly associated with psychiatric comorbidity in children and young adults with type 1 diabetes, Austrian research shows.

The addition of empagliflozin to insulin therapy reduces glycated hemoglobin levels in patients with type 1 diabetes, indicate findings from the phase III EASE-2 and 3 trials.

Diabetes medications are frequently unavailable and unaffordable, particularly in lower-income countries, shows an analysis of the PURE study.

Lucidi P et al. Curr Diab Rep 2018; 18: 83. doi: 10.1007/s11892-018-1065-6

Carmen Soto and David Strain provide their insights on clinical inertia in diabetes care and present the co-production model of open communication as an innovative means to address this widespread clinical issue.

Oriot P et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1170-7

Sanjay Kalra and Silver Bahendeka, East Africa Diabetes Study Group Chair, provide an overview of the latest insulin guidance developed to aid management in a challenging region, facing familiar struggles.

Modestly increasing glucagon levels when commencing physical activity could be an effective strategy for preventing exercise-induced hypoglycemia among patients with type 1 diabetes, results of a randomized crossover trial suggest.

McDonnell ME. Curr Diab Rep 2018; 18: 42. doi: 10.1007/s11892-018-1015-3

Zivkovic M, Petrovski G, Bitoska I. Acta Diabetol 2018; Advance online publication. doi: 10.1007/s00592-018-1147-6

Diabetes and endocrinology Consultant and Advisory Board member Terence Pang highlights the benefits that a structured approach to glycemic goal setting can bring to your practice and patients with type 1 diabetes.

As the utility and availability of devices surges, so too do patient expectations. Advisory Board member Katharine Barnard provides key consultation questions to help determine your patients’ greatest needs and obstacles.

With the 2017 NaDIA results showing some positive trends in inpatient diabetes care, medwireNews talks to national clinical lead Gerry Rayman about the tools and tactics to deliver the best patient outcomes.

Results of an observational study suggest that doing exercise around the time of type 1 diabetes diagnosis could extend the “honeymoon” period of low insulin requirement.